Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The FEZ1 gene is located on chromosome 8p22, and it encodes a leucine zipper protein with a relative molecular mass of 67 × 103, which has a growth regulation effect. FEZ1 gene plays a very important role in the occurrence and development of many human malignant tumors, including prostate cancer, gastric cancer, head and neck cancer, bladder cancer, hepatocellular carcinoma, cholangiocarcinoma, and hematological malignancies.
Figure 1. FEZ proteins cytoplasmic function as transport bivalent adaptors. (Teixeira, M., et al. 2019)
In lung cancer, the researchers used immunohistochemical methods to analyze 103 cases of primary lung cancer (including 98 cases of non-small cell lung cancer, 57 cases of adenocarcinoma, 32 cases of squamous cell carcinoma, 7 cases of large cell carcinoma, and 2 cases). The expression of FEZ1 gene in 5 cases of other tissue types) and 5 cases of small cell carcinoma. The results showed that 27 cases had FEZ1 gene deletion, and 43 cases had significantly reduced expression. In addition, the results showed that the FEZ1 gene was positively correlated with tumor grade. Therefore, it is believed that FEZ1 gene plays an important role in lung cancer, and it is speculated that it may be used as a new prognostic indicator of lung cancer.
In bladder cancer, researchers used Western blot and immunohistochemistry methods to study the expression of FEZ1 protein in bladder transitional cell carcinoma-derived cell lines and primary bladder cancer. Among the bladder transitional cell carcinoma-derived cell lines, FEZ1 protein was missing or down-regulated in 4/5 cell lines, and FEZ1 protein was missing or down-regulated in 37 of 60 primary cancers. Another 37% of primary transitional cell carcinoma of the bladder and 70% of bladder transitional cell carcinoma-derived cell lines showed a significant decrease in FEZ1 protein expression. At the same time, statistical analysis showed that the down-regulation and lack of FEZ1 expression are significantly correlated with the grade of bladder cancer. In addition, studies have shown that the mRNA level and transcription products of FEZ1 gene are significantly reduced in most bladder transitional cell carcinoma-derived cell lines and primary bladder cancer, and it is believed that the mechanism of FEZ1 gene inactivation may be the promoter hypermethylation.
Using gastric cancer carcinogen NMBA to induce tumors in mice lacking endogenous FEZ1 gene to study the role of FEZ1 in living tumors. The results of the study showed that after 6 weeks of administration, FEZ1 (-/-) mice (20/20) and FEZ1 (+/-) mice had complex tumor growth in the cardiac sinus, while only (5/19) Wild-type mice have the potential to develop tumors. In addition, only the first two types of mice have invasive growth tumors, and wild-type mice show a series of injuries including hyperplasia and papilloma.
It was observed that untreated mice lacking the FEZ1 gene had spontaneous tumors after 2 years. 5 FEZ1 (-/-) and FEZ1 (+/-) mice had new tumor growth, while 3 wild-type mice No new tumors were found in the mice. Observing spontaneous tumors and induced tumors in mice with inactivated FEZ1 alleles, researchers infer that FEZ1 can inhibit the growth of tumor cells. In addition, when researchers studied bladder cancer cell lines lacking the endogenous FEZ1 gene, they were transduced to restore expression in vitro, and they also observed the inhibitory effect of FEZ1 on tumor cell growth. This effect is related to FEZ1's ability to regulate cell mitosis.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.